Futura Medical Share Discussion Threads

[lbo] 13/9/2022 07:27

You think it ‘good’ that there is Zero revenues from the Cooper deal yet shareholders were told an ‘ initial upfront payment’ was being paid. Seems Cooper see so little value in Med3000 they paid nothing upfront for it! Yet they admit they paid others to get the deal signed! LOL

‘ The slight increase mainly relates to legal and professional costs associated with concluding MED3000 commercial agreements’

[keifer derrin] 13/9/2022 07:20

good interims....no need to raise any money and like the fact they say MED3000 will launch in the coming months....

[lbo] 13/9/2022 07:14

Zero revenue in the results from the Cooper deal? Yet back in May the RNS said ‘ Futura will receive an initial upfront payment’?

[lbo] 12/9/2022 16:16

So even if Med3000 does get De Novo Medical device registration after the FM71 study. It still cannot substantiate to the FTC or ASA any effect beyond a placebo with any adequately controlled study









In each of the six cases filed, FTC alleged that the companies not only lacked scientific substantiation for their claims regarding the health benefits of their CBD/CBG products, but also falsely represented that their claims were either scientifically proven or had been confirmed by the U.S. government.

Under the proposed orders settling FTC complaints in each of these cases, the companies and their owners are prohibited from making prevention, treatment, or safety claims similar to the ones the companies made about their products about any dietary supplements, foods, and drugs unless they have the human clinical testing to substantiate such claims, and are required to have competent and reliable scientific evidence for any other health-related product claims. Specifically, the testing must be: (1) randomized, double-blind, and placebo-controlled

[haveapunt1] 12/9/2022 16:04

Nice big £70,000 buy now popped in. Loading continues imo

[j777j] 12/9/2022 15:17

The increasingly frantic ramblings of lbo canute show his desperation of being wholly irrelevant.


24/ 7 for the last 2 years and we will soon smash past record previous highs.

[lbo] 12/9/2022 15:12

Really mike? LOLmikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he saysmikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141Company is massively over valued if you go by 'concrete' results !mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the sharesUnfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591"A couple of decent deals and will be back off to the races."Do you have any idea of how long shareholders have been using these wordsmikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713why should it be any different this time when you've still got the same useless lot running the showmikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-lifeAnd where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remunerationI just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

[mikethebike4] 12/9/2022 15:04

LBO

Think you would win an award for obsessive repetition you know

Do you have any pastimes other than this ?

[lbo] 12/9/2022 14:47

All Futura maybe has done is created a new OTC regulatory category for lubricants/arousal gels in men. Allowing Reckitt etc to exploit the equivalence route and sell lubricants/arousal gels as medical device placebo treatments for ED. And report MED3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that MED3000 itself has no proven effect beyond a placebo. As Med3000 has not proven any efficacy in any adequately controlled placebo controlled study or even against any standard cooling lubricant/arousal gels already on the market.




‘You are the active ingredient’



Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[lbo] 12/9/2022 14:45

LOL Yes do the maths! Even if an alcohol and water gel does somehow manage to capture 5% of the global ED market. It will be the established brands in the lubricants/arousal gel market that see the real revenue. Not Futura. https://futuramedical.com/media/2187/admission_doc.pdf a The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[j777j] 12/9/2022 14:43

At just one time per week that is revenues of £32 million A WEEK.Think about it !

[j777j] 12/9/2022 14:25

Oh how funny people can watch the utter desperation of lbo.Business is dynamic. Lbo's increasingly frequent postings simply highlight his irrelevance. 300 million men 217p wholesale priceEven a tiny 5% market share would value futura in the £££'sDo the maths.

[lbo] 12/9/2022 13:43

Long standing shareholders learned from Futura what clauses have been in previous deals that favour their partners. Just to get the deals signed and announced. But allows the partners to never have to launch or if they do launch never have to pay any real royalties. There was Zero value to shareholders in every so called contract FUM have signed since 2003. And even just allow partners to hand back the rights with no real penalties after sitting on the rights and running down any patents eg Reckitt and CSD500. Or what shareholders remember the deal with Kabey who was supposedly ‘well established’ group and ‘exciting times’ were ahead! Yet Kabey itself no longer even exists? LOL




a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product.

The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[j777j] 12/9/2022 13:35

Launch across the UK and EU imminentUnstoppable now

[lbo] 12/9/2022 13:31

Here is the Med3000 patent application! LOLhttps://patents.google.com/patent/WO2021116651A1/enThe composition of the invention contained: ethanol: 33%; water: 35%; glycerol: 24%; propylene glycol: 6%; Carbopol® Ultrez 10: 1%. pH was adjusted to 5.25 with potassium hydroxide solution. The ethanol used in the manufacture of the composition was absolute ethanol (i.e. 100% ethanol free from water) such that the final composition contained 33% of pure ethanol. If a lower grade of ethanol was used which contained impurity amounts of water (e.g. 96% ethanol), then the amount used would have to be adjusted to ensure the final composition contained the correct amount of the components, i.e. 33% pure ethanol and 35% water.https://saraluna.de/Kama-Sutra-Intensify-Plus-Female-Arousal-Gel-Cooling-15-ml_1Kama Sutra Intensify Plus Female Arousal Gel Cooling 15 mlIngredients: Water, Propylene Glycol, Denatured Alcohol

[lbo] 12/9/2022 13:29

LOL

That anyone including Reckitt can copy and sell their own water, glycol and alcohol gel that also causes evaporative cooling






The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[j777j] 12/9/2022 13:13

Very exciting times ahead300 million men suffer from ED globallyAt 217p per unit wholesale it doesn't take rocket science to see futura will be worth £££'s a share

[lbo] 12/9/2022 11:41

Not short. But anyone who went short from March 2021 is still seriously in the money even if they hadn’t covered when it was down below 30p! LOL

Suspect shorters would be looking to again build short positions on the back of any further share price strength with the De Novo device registration submission announcement, possibly the ramping even around a test launch online somewhere in the EU/UK. Basically what happened with CSD500 until ultimately the realisation sets in there is no real prospect of any significant revenues especially as similar products are launched and ultimately the Med3000 product is deemed a failure. As Liberum said the risks have only moved from regulatory to execution risk. And their execution of bringing PET500, CSD500 and TPR100 to maktet have all been disasters! Yet Reckit has similar products to each of Futura’s failed products still on the market (KY Duration) (Durex warming/Durex intense condoms) (Nurofen pain gel). They even admitted they can’t take on the likes of Reckitt. And that was with a product that had patent protections and some real clinically proven USPs against standard condoms. Which MED3000 does not have.




‘Futura does not have the marketing or regulatory resources to support the day-to-day requirements in a growing compliance-driven medical device market’

‘the immediate potential for substantial royalties is low in the absence of a large global brand 'carrier' to take the product forward’

[losses] 12/9/2022 11:24

LBO getting shafted by his own shorts here!! Buy up and enjoy the ride to 100

[lbo] 12/9/2022 09:23

I am also very interested to even hear how the De Novo registration is a positive? When its clear that all Futura may have done is create a new regulatory category around arousal gel/lubricants with placebo effect for psychological ED. That others including Reckitt can then just copy via the 510k pathway.



‘This De Novo authorization will also allow subsequent devices of the same type and intended use to come to the market through the 510k pathway, which could enable the devices to get on the market faster.”

De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device

The average length of time for clearance under the traditional 510(k) pathway is 177 days,



‘a company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially immediately’

[lbo] 12/9/2022 09:07

I am very interested in Futura. Have been for years.I am even more interested to get an update on an enforceable patent on something that was clearly already described in research literature!?



The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents’



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.